Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
Álvaro Machado,1 Tiago Torres1,2 1Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal Abstract: Psoriasis is a common chronic immune-media...
Guardado en:
Autores principales: | Machado Á, Torres T |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0024f89d204e4d6f81ccd0f66c542e61 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Yuliya Lytvyn, PhD, et al.
Publicado: (2022) -
Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
por: Annunziata Dattola, et al.
Publicado: (2021) -
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: Riccardo G. Borroni, et al.
Publicado: (2021) -
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck KM, et al.
Publicado: (2018) -
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy V, et al.
Publicado: (2020)